Our goal is to collaborate with healthcare providers supporting growth of cancer care infrastructure in India
Elekta, leader in precision radiation therapy recently launched the first Elekta Unity MR-Linac system in India on the 20th of June at Yashoda Hospital in Hyderabad. In an interaction with Kalyani Sharma, Manikandan Bala, Managing Director, India & Senior Vice President, Intercontinental, Elekta talks about this new technology and its characteristics
Tell us more about the newly launched Elekta Unity MR-Linac. What will be its main characteristics and how accessible/affordable is it?
The newly launched Elekta Unity MR-Linac, is a path breaking advancement in the field of radiotherapy. It integrates a high-field 1.5T MRI system with an advanced linear accelerator, providing diagnostic quality visibility while radiating a tumour with precision. It enables medical professionals to provide tailored treatments based on individualised factors, potentially resulting in improved clinical outcomes. Unity’s targeted radiation dose delivery reduces the need for repositioning and re-scanning, streamlining the treatment process and potentially improving treatment outcomes.
We believe that Unity creates immense value for clinicians and patients alike. In terms of accessibility, we believe that all eligible patients should have access to Elekta Unity MR-Linac treatments.
How many countries are currently using Elekta Unity MR-Linac and how do you see its scalability in the Indian market in the future?
Elekta Unity MR-Linac technology is making significant strides globally, with numerous countries embracing its potential. The recent launch of India’s first Unity MR-Linac in Hyderabad highlights the growing interest and positive reception from healthcare providers worldwide. Currently, there are a total of 75 units installed/under installation in 27 countries and 53 are already in clinical use in 22 countries.
Scalability of Unity in the Indian market involves multifaceted considerations. It encompasses not only the availability of the technology but also the essential infrastructure, skilled healthcare professionals and robust ecosystems. Integrating such advanced technology into existing healthcare facilities necessitates meticulous planning and investments.
Elekta recognises the criticality of addressing these factors to ensure the successful adoption and scalability of Unity in India. We actively engage with healthcare stakeholders, including government bodies, hospitals, and clinicians, to comprehend the unique challenges and collaborate on strategies that enhance cancer care delivery.
Our goal is to closely collaborate with healthcare providers and decision-makers, supporting the growth of cancer care infrastructure in India. Leveraging our expertise and fostering collaborations, we aim to bolster capabilities and improve access to cancer treatment, ultimately benefiting patients across the country.
According to you, what are some of the global technologies that should be a part of the Indian healthcare system for better cancer care?
Elekta Unity MR-Linac, without a doubt, is one of the key global technologies that should be integrated into the Indian healthcare system to enhance cancer care. This would empower clinicians with valuable insights, enabling them to make better informed decisions throughout the treatment process. By implementing Unity, India can advance its capabilities in cancer care, providing patients with access to state-of-the-art treatments and positioning the country at the forefront of innovative healthcare solutions. In conclusion, the adoption of global technologies, with Unity at the forefront, is essential for the Indian healthcare system to deliver better cancer care. Apart from this we are very vocal about integrating Oncology Informatics into the larger ecosystem.
It will help with proper capture of incidence, treatment outcomes and guide policy makers in terms of investments across different parts of the country – depending on the type of cancer.
What are your further plans for the Indian market?
Elekta has a strong market presence in India and sees significant growth potential in the country’s healthcare sector, given its large population and rising cancer incidence rates. With India’s large population and increasing incidence of cancer, we aim to deepen our presence by expanding reach to more tier-2 and tier-3 cities and towns.
As part of our commitment to the Indian market, we have plans to expand the presence of radiation therapy systems across the country. Our goal is to ensure that every state in India has access to the best cancer care. We believe that by increasing the availability of radiation therapy systems, we can positively impact cancer care outcomes and reach a larger population in need. To achieve this, we are actively working on partnerships and collaborations with healthcare institutions, government bodies, and industry stakeholders. By fostering these relationships, we aim to create a robust network that will support the widespread adoption of radiation therapy in every district of India.
By embracing contemporary technology and working together towards its widespread implementation, we can transform the landscape of cancer care in India and bring hope to countless lives affected by this disease.
- Advertisement -
